Learn more about our novel target for treatment of chronic inflammatory diseases at Biotrinity – A Leading Biopartnering and Investment Conference in London, April 23-25, 2018

We will tell you more about Bile Salt-Stimulated Lipase (BSSL) and our ongoing development of a therapeutic antibody. Lipum has collected original research data proving the efficacy of the compound in several established arthritis models. The BSSL antibodies effectively block human inflammatory cell migration. We are currently developing a humanized monoclonal antibody that target BSSL and our candidate drug will then be subject for toxicological tests and clinical trials. Lipum is actively seeking investors or partners for a faster development or out-licensing of our technology, read more here